Wall Street analysts expect that BeiGene (NASDAQ:BGNE) will report ($1.96) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for BeiGene’s earnings, with the highest EPS estimate coming in at ($1.87) and the lowest estimate coming in at ($2.00). BeiGene reported earnings of ($1.27) per share in the same quarter last year, which would indicate a negative year over year growth rate of 54.3%. The firm is scheduled to issue its next earnings results on Wednesday, May 9th.
On average, analysts expect that BeiGene will report full-year earnings of ($7.81) per share for the current fiscal year, with EPS estimates ranging from ($8.60) to ($6.77). For the next fiscal year, analysts expect that the business will report earnings of ($8.27) per share, with EPS estimates ranging from ($9.00) to ($7.33). Zacks’ EPS averages are an average based on a survey of analysts that follow BeiGene.
BeiGene (NASDAQ:BGNE) last released its earnings results on Wednesday, February 28th. The company reported ($2.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.40). The company had revenue of $18.17 million during the quarter, compared to the consensus estimate of $23.00 million.
In other BeiGene news, CEO John Oyler sold 34,338 shares of BeiGene stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $146.69, for a total value of $5,037,041.22. Following the transaction, the chief executive officer now directly owns 93,883 shares of the company’s stock, valued at approximately $13,771,697.27. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Howard Liang sold 40,000 shares of BeiGene stock in a transaction that occurred on Monday, March 19th. The stock was sold at an average price of $160.27, for a total value of $6,410,800.00. Following the completion of the transaction, the chief financial officer now directly owns 15,872 shares in the company, valued at $2,543,805.44. The disclosure for this sale can be found here. Insiders sold a total of 194,210 shares of company stock worth $29,041,676 over the last ninety days. Insiders own 19.90% of the company’s stock.
A number of institutional investors have recently made changes to their positions in BGNE. Tower Research Capital LLC TRC purchased a new position in shares of BeiGene during the fourth quarter valued at approximately $182,000. Comerica Bank purchased a new position in shares of BeiGene during the fourth quarter valued at approximately $246,000. Mackenzie Financial Corp purchased a new position in shares of BeiGene during the fourth quarter valued at approximately $250,000. Jefferies Group LLC purchased a new position in shares of BeiGene during the fourth quarter valued at approximately $283,000. Finally, Jane Street Group LLC purchased a new position in shares of BeiGene during the third quarter valued at approximately $339,000. 51.47% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:BGNE opened at $167.99 on Thursday. BeiGene has a 1-year low of $34.36 and a 1-year high of $182.79. The company has a quick ratio of 6.02, a current ratio of 6.09 and a debt-to-equity ratio of 0.23.
COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Anticipate BeiGene (BGNE) to Announce -$1.96 Earnings Per Share” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://stocknewstimes.com/2018/04/22/zacks-analysts-anticipate-beigene-bgne-to-announce-1-96-earnings-per-share.html.
BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.